AG˹ٷ

STOCK TITAN

[8-K/A] SeaStar Medical Holding Corporation Amends Material Event Report

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
8-K/A
Rhea-AI Filing Summary

SeaStar Medical Holding Corporation filed an amendment to its current report to correct an inadvertent EDGAR submission header so the filing references Items 2.02 and 9.01. The amendment states it makes no changes to the substance of the original report.

The original report furnished a press release as Exhibit 99.1 announcing the company's financial condition and results for the three and six months ended June 30, 2025.

SeaStar Medical Holding Corporation ha presentato una modifica al proprio rapporto corrente per correggere un'intestazione inviata per errore a EDGAR, affinché la segnalazione riporti i punti 2.02 e 9.01. La modifica specifica che non vengono apportate variazioni alla sostanza del rapporto originale.

Il rapporto originale includeva un comunicato stampa come allegato 99.1, che annunciava la situazione finanziaria e i risultati della società per i tre e i sei mesi chiusi al 30 giugno 2025.

SeaStar Medical Holding Corporation presentó una enmienda a su informe actual para corregir un encabezado enviado por error a EDGAR, de modo que el documento haga referencia a los ítems 2.02 y 9.01. La enmienda indica que no introduce cambios en el contenido del informe original.

El informe original adjuntó un comunicado de prensa como anexo 99.1 que anunciaba la situación financiera y los resultados de la compañía para los tres y seis meses terminados el 30 de junio de 2025.

SeaStar Medical Holding Corporation� 우발적인 EDGAR 제출 헤더� 수정하여 제출 문서가 항목 2.02 � 9.01� 참조하도� 하기 위해 현재 보고서에 대� 수정안을 제출했습니다. 해당 수정안은 원래 보고서의 내용에는 변경이 없다� 명시하고 있습니다.

� 보고서에� 회사� 재무상태 � 2025� 6� 30일로 종료되는 3개월 � 6개월 기간� 실적� 알리� 보도자료가 증빙서류 99.1� 첨부되어 있었습니�.

SeaStar Medical Holding Corporation a déposé un amendement à son rapport courant afin de corriger un en-tête de soumission EDGAR erroné, de sorte que le dépôt fasse référence aux éléments 2.02 et 9.01. L'amendement précise qu'il n'apporte aucune modification au fond du rapport original.

Le rapport initial comprenait un communiqué de presse en annexe 99.1 annonçant la situation financière et les résultats de la société pour les trois et six mois clos le 30 juin 2025.

SeaStar Medical Holding Corporation reichte eine Änderung ihres aktuellen Berichts ein, um eine versehentliche EDGAR-Übermittlungsüberschrift zu korrigieren, sodass die Einreichung auf die Punkte 2.02 und 9.01 verweist. In der Änderung wird angegeben, dass am Inhalt des ursprünglichen Berichts keine Änderungen vorgenommen werden.

Der ursprüngliche Bericht enthielt eine Pressemitteilung als Anlage 99.1, in der die finanzielle Lage des Unternehmens und die Ergebnisse für die drei und sechs Monate zum 30. Juni 2025 bekanntgegeben wurden.

Positive
  • EDGAR header corrected so the submission references the appropriate Item numbers (Items 2.02 and 9.01).
  • Press release furnished as Exhibit 99.1 reporting the company's financial condition and results for the three and six months ended June 30, 2025.
Negative
  • None.

Insights

TL;DR: This is an administrative correction; substantive disclosures unchanged and a press release on quarterly results was furnished as an exhibit.

The amendment corrects an EDGAR header referencing the wrong Item number and confirms no changes to the original 8-K content. Because the filing only updates metadata and reiterates that the press release is furnished rather than filed, there is minimal direct impact on the company's financial disclosures or investor valuation based on this amendment alone.

TL;DR: Correcting filing metadata improves disclosure accuracy but does not alter the companys reported information; governance impact is procedural.

The amendment addresses an inadvertent EDGAR submission error to reference Items 2.02 and 9.01 correctly. This is a governance/administrative fix that enhances the accuracy of public records. It explicitly states there are no substantive changes to the original filing, so it should not affect the companys regulatory standing or change investor assessment based on the original disclosures.

SeaStar Medical Holding Corporation ha presentato una modifica al proprio rapporto corrente per correggere un'intestazione inviata per errore a EDGAR, affinché la segnalazione riporti i punti 2.02 e 9.01. La modifica specifica che non vengono apportate variazioni alla sostanza del rapporto originale.

Il rapporto originale includeva un comunicato stampa come allegato 99.1, che annunciava la situazione finanziaria e i risultati della società per i tre e i sei mesi chiusi al 30 giugno 2025.

SeaStar Medical Holding Corporation presentó una enmienda a su informe actual para corregir un encabezado enviado por error a EDGAR, de modo que el documento haga referencia a los ítems 2.02 y 9.01. La enmienda indica que no introduce cambios en el contenido del informe original.

El informe original adjuntó un comunicado de prensa como anexo 99.1 que anunciaba la situación financiera y los resultados de la compañía para los tres y seis meses terminados el 30 de junio de 2025.

SeaStar Medical Holding Corporation� 우발적인 EDGAR 제출 헤더� 수정하여 제출 문서가 항목 2.02 � 9.01� 참조하도� 하기 위해 현재 보고서에 대� 수정안을 제출했습니다. 해당 수정안은 원래 보고서의 내용에는 변경이 없다� 명시하고 있습니다.

� 보고서에� 회사� 재무상태 � 2025� 6� 30일로 종료되는 3개월 � 6개월 기간� 실적� 알리� 보도자료가 증빙서류 99.1� 첨부되어 있었습니�.

SeaStar Medical Holding Corporation a déposé un amendement à son rapport courant afin de corriger un en-tête de soumission EDGAR erroné, de sorte que le dépôt fasse référence aux éléments 2.02 et 9.01. L'amendement précise qu'il n'apporte aucune modification au fond du rapport original.

Le rapport initial comprenait un communiqué de presse en annexe 99.1 annonçant la situation financière et les résultats de la société pour les trois et six mois clos le 30 juin 2025.

SeaStar Medical Holding Corporation reichte eine Änderung ihres aktuellen Berichts ein, um eine versehentliche EDGAR-Übermittlungsüberschrift zu korrigieren, sodass die Einreichung auf die Punkte 2.02 und 9.01 verweist. In der Änderung wird angegeben, dass am Inhalt des ursprünglichen Berichts keine Änderungen vorgenommen werden.

Der ursprüngliche Bericht enthielt eine Pressemitteilung als Anlage 99.1, in der die finanzielle Lage des Unternehmens und die Ergebnisse für die drei und sechs Monate zum 30. Juni 2025 bekanntgegeben wurden.

0001831868true0001831868us-gaap:WarrantMember2025-08-132025-08-1300018318682025-08-132025-08-130001831868us-gaap:CommonStockMember2025-08-132025-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

 

 

SeaStar Medical Holding Corporation

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39927

85-3681132

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3513 Brighton Blvd,

Suite 410

 

Denver, Colorado

 

80216

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 844 427-8100

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock par value $0.0001 per share

 

ICU

 

The Nasdaq Stock Market LLC

Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share

 

ICUCW

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Explanatory Note

This Amendment No. 1 to Form 8-K (this "Amendment") amends Form 8-K of SeaStar Medical Holding Corporation (the "Company") that was originally filed with the Securities and Exchange Commission on August 13, 2025, (the "Original Filing"). This Amendment is being filed solely to correct an inadvertent error in the submission of the Original Filing through EDGAR which referenced the incorrect Form 8-K Item Number (Item 2.01) in the EDGAR submission header. This Amendment is being filed through EDGAR to reference the correct Form 8-K Item Numbers (Items 2.02 and 9.01) in the EDGAR submission header. There are no changes to the Original Filing itself (which referenced the correct Item numbers). Except as summarized above, this Amendment continues to speak as of the date of the Original Filing and does not reflect events occurring after the date of the Original Filing or modify or update the disclosures therein in any way.

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, the Company issued a press release announcing its financial condition and results of operations for the three and six months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1.

 

The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, is deemed to be “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is not otherwise subject to the liabilities of that Section, and shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

 

 

Exhibit

No.

Description

 

 

 99.1

Press Release dated August 13, 2025

 

 

 104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SeaStar Medical Holding Corporation

 

 

By:

/s/ Eric Schlorff

Date:

August 14, 2025

Name:

Eric Schlorff

 

 

Title:

Chief Executive Officer

 


FAQ

What does the SeaStar Medical (ICU) 8-K/A amend?

The amendment corrects an inadvertent EDGAR submission header that referenced the wrong Item number and updates the header to reference Items 2.02 and 9.01; it does not change the original filing's disclosures.

Does this 8-K/A change SeaStar's reported financial results?

No. The amendment explicitly states there are no changes to the original filing and does not modify or update the disclosures about results of operations or financial condition.

What exhibit was furnished with the original report?

Exhibit 99.1 is a press release dated August 13, 2025 announcing SeaStars financial condition and results for the three and six months ended June 30, 2025; Exhibit 104 is the cover page interactive data file.

Is the press release considered filed or furnished under the Exchange Act?

The filing states the information, including the press release furnished as Exhibit 99.1, is deemed "furnished" and not "filed" for purposes of Section 18 of the Exchange Act.

Who signed the amendment for SeaStar Medical?

The amendment was signed by Eric Schlorff, Chief Executive Officer on behalf of SeaStar Medical Holding Corporation.
SeaStar Medical Holding Corp

NASDAQ:ICU

ICU Rankings

ICU Latest News

ICU Latest SEC Filings

ICU Stock Data

20.26M
27.63M
1.31%
5.23%
2.55%
Biotechnology
Surgical & Medical Instruments & Apparatus
United States
DENVER